Spine Center, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241262483. doi: 10.1177/15330338241262483.
Spinal cord astrocytoma (SCA) is a rare subtype of astrocytoma, posing challenges in diagnosis and treatment. Low-grade SCA can achieve long-term survival solely through surgery, while high-grade has a disappointing prognosis even with comprehensive treatment. Diagnostic criteria and standard treatment of intracranial astrocytoma have shown obvious limitations in SCA. Research on the molecular mechanism in SCA is lagging far behind that on intracranial astrocytoma. In recent years, huge breakthroughs have been made in molecular pathology of astrocytoma, and novel techniques have emerged, including DNA methylation analysis and radiomics. These advances are now making it possible to provide a precise diagnosis and develop corresponding treatment strategies in SCA. Our aim is to review the current status of diagnosis and treatment of SCA, and summarize the latest research advancement, including tumor subtype, molecular characteristics, diagnostic technology, and potential therapy strategies, thus deepening our understanding of this uncommon tumor type and providing guidance for accurate diagnosis and treatment.
脊髓星形细胞瘤(SCA)是星形细胞瘤的一种罕见亚型,在诊断和治疗方面带来挑战。低级别 SCA 仅通过手术即可实现长期生存,而高级别 SCA 即使接受综合治疗预后也较差。SCA 的诊断标准和颅内星形细胞瘤的标准治疗已显示出明显的局限性。SCA 分子机制的研究远远落后于颅内星形细胞瘤。近年来,星形细胞瘤的分子病理学取得了巨大突破,出现了新的技术,包括 DNA 甲基化分析和放射组学。这些进展使得在 SCA 中进行精确诊断和制定相应的治疗策略成为可能。我们旨在回顾 SCA 的诊断和治疗现状,并总结最新的研究进展,包括肿瘤亚型、分子特征、诊断技术和潜在的治疗策略,从而加深对这种罕见肿瘤类型的认识,并为准确诊断和治疗提供指导。